FCRL5 and infection: The expert panel members recognize that BsAbs with targets other than BCMA, such as GPRC5D and Fc receptor-homolog 5 (FcRH5), may have variable infection rates and risks, depending on doses, dose intervals, and patient characteristics, and future recommendations may need to take into account these variables.